Literature DB >> 3303951

An immunohistochemical and serum ELISA study of type I and III procollagen aminopropeptides in primary biliary cirrhosis.

B H Davis, J A Madri.   

Abstract

By means of ELISA methodology, the aminopropeptides of Type I and Type III procollagen were measured in the serum of a group of patients with primary biliary cirrhosis. The corresponding liver biopsies were graded blindly for degrees of fibrosis and inflammation. When available, paraffin-embedded liver specimens underwent immunoperoxidase staining for mature Type I and III collagen as well as the aminopropeptides of Type I and III procollagen. Regardless of the degree of fibrosis or inflammation, serum levels of the aminopropeptide of Type I remained within normal limits. In contrast, serum levels of the aminopropeptide of Type III procollagen were elevated uniformly. Immunohistochemistry demonstrated that the aminopropeptide of Type III procollagen persists extracellularly. This finding may explain the previously reported relationship between levels of inflammation and serum levels of the Type III aminopropeptide.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3303951      PMCID: PMC1899633     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  28 in total

1.  Isolation, chemical and electron microscopical characterization of neutral-salt-soluble type III collagen and procollagen from fetal bovine skin.

Authors:  R Timpl; R W Glanville; H Nowack; H Wiedemann; P P Fietzek; K Kühn
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1975-11

2.  Preparation and use in immunohistology of antibodies specific for type I and type III collagen and procollagen.

Authors:  H Nowack; S Gay; G Wick; U Becker; R Timpl
Journal:  J Immunol Methods       Date:  1976       Impact factor: 2.303

3.  Serum procollagen type III peptide as a marker of hepatic fibrogenesis in alcoholic hepatitis.

Authors:  M Torres-Salinas; A Parés; J Caballería; W Jiménez; D Heredia; M Bruguera; J Rodés
Journal:  Gastroenterology       Date:  1986-05       Impact factor: 22.682

4.  Radioimmunoassay for type III procollagen peptide and its application to human liver disease.

Authors:  H Rohde; L Vargas; E Hahn; H Kalbfleisch; M Bruguera; R Timpl
Journal:  Eur J Clin Invest       Date:  1979-12       Impact factor: 4.686

5.  Blood analysis for liver cirrhosis.

Authors:  E G Hahn
Journal:  J Hepatol       Date:  1985       Impact factor: 25.083

6.  Cell types involved in collagen and fibronectin production in normal and fibrotic human liver.

Authors:  B Clement; J A Grimaud; J P Campion; Y Deugnier; A Guillouzo
Journal:  Hepatology       Date:  1986 Mar-Apr       Impact factor: 17.425

7.  Ultrastructural localization of type III procollagen in baboon liver.

Authors:  S Sato; M A Leo; C S Lieber
Journal:  Am J Pathol       Date:  1986-02       Impact factor: 4.307

8.  Steroid treatment lowers hepatic fibroplasia, as explored by serum aminoterminal procollagen III peptide, in chronic liver disease.

Authors:  G Ballardini; A Faccani; F B Bianchi; M Fallani; D Patrono; M Capelli; E Pisi
Journal:  Liver       Date:  1984-12

9.  Procollagen: biological scission of amino and carboxyl extension peptides.

Authors:  L I Fessler; N P Morris; J H Fessler
Journal:  Proc Natl Acad Sci U S A       Date:  1975-12       Impact factor: 11.205

10.  Type III procollagen peptide and PZ-peptidase serum levels in pre-cirrhotic liver diseases.

Authors:  A Morelli; A Vedovelli; S Fiorucci; G P Angelini; C Fini; C A Palmerini; A Floridi
Journal:  Clin Chim Acta       Date:  1985-05-30       Impact factor: 3.786

View more
  2 in total

1.  Temporal regulation of venous extracellular matrix components during arteriovenous fistula maturation.

Authors:  Michael R Hall; Kota Yamamoto; Clinton D Protack; Masayuki Tsuneki; Go Kuwahara; Roland Assi; Kirstyn E Brownson; Hualong Bai; Joseph A Madri; Alan Dardik
Journal:  J Vasc Access       Date:  2014-09-08       Impact factor: 2.283

2.  Biochemical markers of bone formation in the study of postmenopausal osteoporosis.

Authors:  C Dominguez Cabrera; M Sosa Henríquez; M L Traba; E Alvarez Villafañe; C de la Piedra
Journal:  Osteoporos Int       Date:  1998       Impact factor: 4.507

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.